Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerapolturev in advanced solid tumors and NMIBC
NCT04690699Phase 2Terminated
- Sponsor
- Istari Oncology
- Start
- Aug 2021
- Primary completion
- Apr 2024
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lerapolturev in non-muscle-invasive bladder cancer (NMIBC), solid tumor, sponsored by Istari Oncology. Started Aug 2021; status: terminated.
02
Drugs
lerapolturev
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)solid tumor
Beyond the preview
Go deeper on NCT04690699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690699.